Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: Risk factors and outcomes

International Journal of Infectious Diseases

Volumn 16, Issue 5, 2012, Pages

  Freeman, Joshua T ^a   McBride, Stephen J ^b   Nisbet, Mitzi S ^c   Gamble, Greg D ^d   Williamson, Deborah A ^a   Taylor, Susan L ^b   Holland, David J ^b  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b MIDDLEMORE HOSPITAL   (New Zealand)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Colonization; Community onset bacteremia; Empirical therapy; ESBL; Fluoroquinolones; Risk factors

Indexed keywords

CEPHALOSPORIN; CIPROFLOXACIN; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BLOOD CULTURE; BLOODSTREAM INFECTION; CATHETER INFECTION; CONTROLLED STUDY; DRUG EXPOSURE; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE BACTEREMIA; FEMALE; HOSPITAL ADMISSION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; NEW ZEALAND; OUTCOME ASSESSMENT; RISK ASSESSMENT; TERTIARY HEALTH CARE; TREATMENT DURATION; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL INFECTIONS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; FLUOROQUINOLONES; HOSPITALS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEW ZEALAND; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84859633939     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.01.008     Document Type: Article

References (14)

1. Heffernan H, Woodhouse R. Annual survey of extended-spectrum β-lactamase producing Enterobacteriaceae 2009. New Zealand: Institute of Environmental Science and Research; 2009. Available at: (accessed 28th February 2012). http://www.surv.esr.cri.nz/PDF_surveillance/Antimicrobial/ESBL/ESBL_2009.pdf.
2. Tumbarello M., Sali M., Trecarichi E.M., Leone F., Rossi M., Fiori B., et al. Bloodstream infections caused by extended spectrum-β-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 2008, 52:3244-3252.
3. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. CLSI document M100-S15. Wayne, PA: CLSI; 2005.
4. Thomson K.S. Controversies about extended-spectrum and AmpC β-lactamases. Emerg Infect Dis 2001, 7:333-336.
5. Pitout J.D., Gregson D.B., Church D.L., Elsayed S., Laupland K.B. Community-wide outbreaks of clonally related CTX-M-14 β-lactamase-producing Escherichia coli strains in the Calgary health region. J Clin Microbiol 2005, 43:2844-2849.
6. Woodford N., Ward M., Kaufmann J., Turton J., Fagan E.J., James D., et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 2004, 54:735-743.
7. Oteo J., Navarro C., Delgado-Iribarren A., Wilhelmi I., Orden B., Garcia C., et al. Spread of Escherichia coli strains with high level cefotaxime and ceftazidime resistance between the community, long term care facilities and hospital institutions. J Clin Microbiol 2006, 44:2359-2366.
8. Russo T.Z., Johnson J.R. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect 2003, 5:449-456.
9. Ben Ami R., Schwaber M.J., Nanon-Venezia S., Schwartz D., Giladi M., Chmelnitsky I., et al. Influx of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis 2006, 42:925-934.
10. Rodríguez-Baño J., Navarro M.D., Romero L., et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalised patients. J Clin Microbiol 2004, 42:1089-1094.
11. Rodríguez-Baño J., Picón E., Gijón P., Henandez J.R., Ruiz M., Pena C., et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010, 50:40-48.
12. Peirano G., Pitout J.D. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 2010, 35:316-321.
13. McCormack J., Grayson L. The use of antibiotics 2010, 1288. Hodder Arnold/ASM Press, Washington DC, Part 11, Chapter 93. 6th ed. L. Grayson (Ed.).
14. Donskey C.J. Antibiotic regimens and intestinal colonization with antibiotic-resistant Gram-negative bacilli. Clin Infect Dis 2006, 43(Suppl 2):S62-S69.